Higher contribution from specialty and strong domestic franchise is likely to change the product mix towards more remunerative businesses b...

The analyst suggested a stoploss at Rs 410 .

The nature of the observations will be understood once the FDA makes Form 483 public, said Morgan Stanley.

Buy Sun Pharmaceutical Industries Ltd. at a price target of Rs 455.0 and a stoploss at Rs 425 from entry point.

The analyst suggested a stoploss at Rs 435.

Buy Sun Pharmaceutical Industries Ltd. at a price target of Rs 450.0 and a stoploss at Rs 433 from entry point.

Jay Thakkar recommended to keep stoploss at Rs 408.

Sell Sun Pharmaceutical Industries Ltd. at a price target of Rs 395.0 and a stoploss at Rs 422 from entry point.

Buy Sun Pharmaceutical Industries Ltd. at a price target of Rs 458.0 and a stoploss at Rs 425 from entry point.

Buy Sun Pharmaceutical Industries Ltd. at a price target of Rs 475.0 and a stoploss at Rs 443 from entry point.

Buy Sun Pharmaceutical Industries Ltd. at a price target of Rs 448.0 and a stoploss at Rs 432 from entry point.

Sell Sun Pharmaceutical Industries Ltd. at a price target of Rs 545.0 and a stoploss at Rs 593 from entry point.

Buy Sun Pharmaceutical Industries at a price target of Rs 655 and a stop loss at Rs 588 from the entry point.

Sell Sun Pharmaceutical Industries Ltd. at a price target of Rs 565.0 and a stoploss at Rs 600 from entry point.

"We have a strong taxation practice but with this merger, our taxation practice will be one of the strongest in the co untry," said Dilip B...

As per the new operational integration design, all new firms would now come under one umbrella and called Baker Tilly DHC.

The alliance will herald the emergence of domestic consultancy firms in the global domain, which is dominated by the Big Four.